pulmonary fibrosis treatment guidelines

Pulmonary Fibrosis Treatment Guidelines

Pulmonary fibrosis treatment guidelines have been developed to diagnose and treat the symptoms of this progressive lung disease. Pulmonary fibrosis is most commonly treated using either medication, which helps to decrease inflammation, or oxygen therapy, which helps to increase the levels of oxygen in the blood. For some people living with pulmonary fibrosis, these treatments can effectively minimize their symptoms. Traditional treatment often has unwanted side effects, however, and does not work for everyone.

At the Lung Institute, our approach to treating pulmonary fibrosis includes a natural alternative to traditional methods: stem cell therapy. Using regenerative medicine to treat lung disease has the potential to slow the progression of pulmonary fibrosis and improve the overall function of the lungs, all while helping to manage the symptoms associated with the condition.

We offer two different forms of stem cell therapy at the Lung Institute:

  • Venous stem cell therapy, in which the stem cells are derived from the patient’s blood
  • Bone marrow stem cell therapy, in which the stem cells are taken from a small amount of the patient’s bone marrow

Both of these procedures are performed by experienced professionals who utilize minimally invasive techniques, and both types of treatment are administered on an outpatient basis over the course of two days. And because our stem cell treatments use autologous stem cells, or stem cells derived from the patient’s own body, they have minimal risk of side effects and the risk of rejection is virtually nonexistent.

To learn more about pulmonary fibrosis treatment guidelines as it relates to stem cell therapy available at the Lung Institute, call our team today at (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.